Incyte's LifeSeq Gold® Database Wins Scientific Computing & Instrumentation's Readers Choice Award Palo Alto, CA, and San Diego, CA, August 1, 2001 -- Incyte Genomics, the leading genomics information company, today announced that its respected database - LifeSeq Gold® - won Scientific Computing & Instrumentation's 10th annual Readers' Choice Award for Bioinformatics software. This is the second consecutive year LifeSeq Gold® has won the award. "SC&I's Readers' Choice Awards recognize products used by a highly educated and experienced pool of scientists and technical professionals. These products have been chosen based on their high level of reliability and quality, as well as their ability to enhance productivity and innovation," said Editor-in-Chief Kim Sekel. Incyte's LifeSeq Gold® is the first commercially available database to combine cDNA transcripts and genomic sequence data into the single "best view" of the human genome. The database integrates more than seven million cDNA sequences (of which more than three quarters are proprietary to Incyte), integrated with the public human genome sequence data that provides a comprehensive view of the human transcriptome. The gene sequences are extracted from more than 1,400 cDNA normal and disease tissue libraries that were derived from more than 900 individuals. In addition, LifeSeq Gold® provides full-length sequences of the most pharmaceutically relevant drug targets and therapeutics, as well as access to verified clone reagents. "We are thrilled that SC&I's readers chose Gold two years in a row," said Roy Whitfield, Incyte's CEO. "This award reaffirms Incyte's commitment to the development of leading-edge tools and solutions for biopharma and academic researchers. Because our data is unique, it is superior to the content in the public domain or to that derived from gene prediction processes, rendering it invaluable to research activity." At the Drug Discovery Technology 2001 conference in August in Boston, Incyte will introduce the next generation LifeSeq® database. Concentrating on functional genomics, the enhanced database will contain the world's largest collection of pharmaceutically relevant full-length gene transcripts anchored to the finished public genomic sequence. Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the unparalleled content of Incyte's forthcoming LifeSeq® database products and the utility of Incyte's products in third-party research programs, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the extent to which genomic databases are utilized in biopharma and academic research and development programs; the ability of Incyte to provide products and services that meet market needs and demand; the impact of competition and the speed at which competitors bring competing products to market; the impact of alternative technologies, processes and approaches; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2001. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward-looking statements.